Author:
Thangamani Shankar,Mohammad Haroon,Abushahba Mostafa F. N.,Hamed Maha I.,Sobreira Tiago J. P.,Hedrick Victoria E.,Paul Lake N.,Seleem Mohamed N.
Publisher
Springer Science and Business Media LLC
Reference57 articles.
1. Cziraky, M. J., Watson, K. E. & Talbert, R. L. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting. J Manag Care Pharm 14, S3–28, quiz S30-21 (2008).
2. Shitara, Y. & Sugiyama, Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacology & therapeutics 112, 71–105 (2006).
3. McTaggart, F. et al.Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. The American journal of cardiology 87, 28B–32B (2001).
4. Liao, J. K. & Laufs, U. Pleiotropic effects of statins. Annual review of pharmacology and toxicology 45, 89–118 (2005).
5. Parihar, S. P. et al.Simvastatin enhances protection against Listeria monocytogenes infection in mice by counteracting Listeria-induced phagosomal escape. PloS one 8, e75490 (2013).
Cited by
106 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献